1.13.11.33 (-)-5,7-O-diacetyl-3',4',5'-O-triacetylepigallocatechin-3-O-(3'',4'',5''-O-triacetyl)gallate IC50: 0.061 mM 62160 1.13.11.33 (-)-5,7-O-dibutyryl-3',4',5'-O-tributyrylepigallocatechin-3-O-(3'',4'',5''-O-tributyryl) gallate IC50: 0.033 mM 62161 1.13.11.33 (-)-5,7-O-dimethyl-3',4',5'-O-trimethylepigallocatechin-3-O-(3'',4'',5''-O-trimethyl) gallate IC50: 0.03 mM 62162 1.13.11.33 (-)-5,7-O-dipropionyl-3',4',5'-O-tripropionylepigallocatechin-3-O-(3'',4'',5''-O-tripropionyl) gallate IC50: 0.031 mM 62159 1.13.11.33 (-)-epigallocatechin-3-gallate IC50: 0.1 mM 2518 1.13.11.33 (-)-jaspic acid IC50: 0.0014 mM 62165 1.13.11.33 (Z)-9-octadecenyl sulfate allosteric inhibition 112106 1.13.11.33 1,2,3-triphenylindolizine-7-carbonitrile IC50: 0.028 mM 56666 1.13.11.33 1-(((2,4,6-trimethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.017 mM 56796 1.13.11.33 1-(((2,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.027 mM 56800 1.13.11.33 1-(((2,5-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.015 mM 56802 1.13.11.33 1-(((2-methyl)ethylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.042 mM 56792 1.13.11.33 1-(((2-methyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.022 mM 56795 1.13.11.33 1-(((2-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.021 mM 56803 1.13.11.33 1-(((3,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.019 mM 56801 1.13.11.33 1-(((3-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.023 mM 56804 1.13.11.33 1-(((4-(2-methylethyl)phenl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.016 mM 56797 1.13.11.33 1-(((4-chlorophenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.022 mM 56805 1.13.11.33 1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile IC50: 0.025 mM 56799 1.13.11.33 1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.025 mM 56798 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile IC50: 0.2 mM 56781 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile IC50: 0.22 mM 56780 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile IC50: 0.024 mM 56783 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile IC50: 0.2 mM 56782 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-dibutyl-7-indolizinecarbonitrile IC50: 0.03 mM 56785 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diethyl-7-indolizinecarbonitrile IC50: 0.029 mM 56784 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarboxaldehyde IC50: 0.02 mM 56787 1.13.11.33 1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinylethanone IC50: 0.023 mM 56788 1.13.11.33 1-(((4-methysulfonyllphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.024 mM 56807 1.13.11.33 1-(((4-trifluoromethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.023 mM 56806 1.13.11.33 1-((4-methylphenyl)sulfonyl)2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.029 mM 56808 1.13.11.33 1-((butylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.028 mM 56791 1.13.11.33 1-((methylsulfonyl)oxy)-2,3-diphenyl-7-indolizine-carbonitrile IC50: 0.022 mM 56790 1.13.11.33 1-((N,N-dimethylaminosulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.025 mM 56793 1.13.11.33 1-((phenylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.024 mM 56794 1.13.11.33 1-(1,3-dibenzyloxy-2-propyloxy)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.031 mM 56821 1.13.11.33 1-(1-Hydroxy-1-phenyl-ethyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.017 mM 56674 1.13.11.33 1-(1-hydroxyethyl)-2,3-diphenylindolizine-7-carbonitrile IC50: 0.026 mM 56673 1.13.11.33 1-(2-furyl)-2,3-diphenylindolizine-7-carbonitrile IC50: 0.024 mM 56669 1.13.11.33 1-(2-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.02 mM 56668 1.13.11.33 1-(2-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.029 mM 56820 1.13.11.33 1-(3-chlorobenzoyl)-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide - 220075 1.13.11.33 1-(3-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.031 mM 56819 1.13.11.33 1-(3-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.02 mM 56667 1.13.11.33 1-(4-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.031 mM 56815 1.13.11.33 1-(4-fluorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.035 mM 56816 1.13.11.33 1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.02 mM 23250 1.13.11.33 1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.037mM 23250 1.13.11.33 1-(4-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.032 mM 56818 1.13.11.33 1-(4-methylphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.037 mM 56817 1.13.11.33 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one - 220066 1.13.11.33 1-(Cyclohexyl-hydroxy-methyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.023 mM 56678 1.13.11.33 1-(Hydroxy-p-tolyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.022 mM 56676 1.13.11.33 1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.035 mM 23254 1.13.11.33 1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.048 mM 23254 1.13.11.33 1-(hydroxymethyl)-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.026 mM 56825 1.13.11.33 1-(hydroxymethyl)-2,3-diphenylindolizine-7-carbonitrile IC50: 0.034 mM 56672 1.13.11.33 1-(Methoxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.021 mM 56679 1.13.11.33 1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile IC50: 0.031 mM 22275 1.13.11.33 1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile IC50: 0.075 mM 22275 1.13.11.33 1-acetyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.023 mM 23252 1.13.11.33 1-acetyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.044 mM 23252 1.13.11.33 1-acetyl-N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide - 220077 1.13.11.33 1-benzoyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.023 mM 23253 1.13.11.33 1-benzoyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.043 mM 23253 1.13.11.33 1-benzyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.027 mM 56665 1.13.11.33 1-benzyl-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide - 220086 1.13.11.33 1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.027 mM 23286 1.13.11.33 1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.039 mM 23286 1.13.11.33 1-formyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.029 mM 23251 1.13.11.33 1-formyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.061 mM 23251 1.13.11.33 1-methoxy-2,3-diphenylindolizine-7-carbonitrile IC50: 0.033 mM 22039 1.13.11.33 1-methoxy-2,3-diphenylindolizine-7-carbonitrile IC50: 0.077 mM 22039 1.13.11.33 1-methyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.027 mM 22274 1.13.11.33 1-methyl-2,3-diphenylindolizine-7-carbonitrile IC50: 0.046 mM 22274 1.13.11.33 1-phenyl-2-([[4-(trifluoromethyl)phenyl]methyl]sulfanyl)-1H-imidazole mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2 260982 1.13.11.33 1-phenylmethoxy-2,3-diphenyl-7-indolizinecarbonitrile IC50: 0.031 mM 56814 1.13.11.33 1-[(2H-1,3-benzodioxol-5-yl)carbamothioyl]-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220083 1.13.11.33 1-[(4-Chloro-phenyl)-hydroxy-methyl]-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.023 mM 56675 1.13.11.33 1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one - 220067 1.13.11.33 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine - 220071 1.13.11.33 1-[4-[4-([[5-(3-chlorophenyl)furan-2-yl]methyl]amino)phenyl]piperazin-1-yl]ethan-1-one - 220064 1.13.11.33 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine - 209062 1.13.11.33 1-[Hydroxy-(4-methoxy-phenyl)-methyl]-2,3-diphenyl-indolizine-7-carbonitrile IC50: 0.017 mM 56677 1.13.11.33 11-hydroxytephrosin IC50: 0.071 mM 62154 1.13.11.33 11-thialinoleic acid is a noncompetitive inhibitor of 15-lipoxygenase-1 with respect to arachidonate or linoleic acid as substrates. Presence of inhibitor does not alter the product distribution for 15-lipoxygenase-1. It does not change the regioselectivity of 15-lipoxygenase-1 19100 1.13.11.33 12alpha-hydroxydeguelin IC50: 0.018 mM 62152 1.13.11.33 12alpha-hydroxyrotenone IC50: 0.102 mM 62153 1.13.11.33 13S-hydroperoxy-9E,11E-octadecydienoic acid rapidly inactivates 112244 1.13.11.33 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol IC50: 0.007 mM 13656 1.13.11.33 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol IC50: 0.0018 mM 13656 1.13.11.33 2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol IC50: 0.00079 mM 51808 1.13.11.33 2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol IC50: 0.0022 mM 51799 1.13.11.33 2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile IC50: 0.033 mM 56810 1.13.11.33 2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile IC50: 0.03 mM 56809 1.13.11.33 2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile IC50: 0.027 mM 56811 1.13.11.33 2,3-Dihydroxybenzoic acid 47.7% inhibition at 0.015 mM, active site binding structure 3773 1.13.11.33 2,3-diphenyl-1-(2-thienyl)indolizine-7-carbonitrile IC50: 0.02 mM 56670 1.13.11.33 2,3-diphenyl-1-(3-thienyl)indolizine-7-carbonitrile IC50: 0.019 mM 56671 1.13.11.33 2,3-diphenyl-1-indolizinol tosylate IC50: 0.025 mM 56786 1.13.11.33 2,3-diphenylindolizine-7-carbonitrile IC50: 0.03 mM 22136 1.13.11.33 2,3-diphenylindolizine-7-carbonitrile IC50: 0.051 mM 22136 1.13.11.33 2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol IC50: 0.01 mM 23036 1.13.11.33 2,4-Dibromophenol IC50: 0.034 mM 5091 1.13.11.33 2,4-dihydroxybenzoic acid 49.9% inhibition at 0.015 mM, active site binding structure 12297 1.13.11.33 2,5-dihydroxybenzoic acid 21.2% inhibition at 0.015 mM, active site binding structure 6417 1.13.11.33 2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol IC50: 0.005 mM 23039 1.13.11.33 2-(1H-indol-3-yl)-N-[(4-pentylphenyl)sulfonyl]acetamide - 134816 1.13.11.33 2-(1H-pyrazol-3-yl)-1,3-benzoxazole - 220140 1.13.11.33 2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole - 220062 1.13.11.33 2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2 220062 1.13.11.33 2-(4-ethylpiperazin-1-yl)4-methylpyrimido[4,5-b][1,4]benzothiazine - 68695 1.13.11.33 2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67863 1.13.11.33 2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67864 1.13.11.33 2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67865 1.13.11.33 2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine - 68700 1.13.11.33 2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67866 1.13.11.33 2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67867 1.13.11.33 2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole - 83060 1.13.11.33 2-alkyl benzopyran-4-ones weak inhibition of isozymes 15-hLO-1 and 15-hLO-2 68692 1.13.11.33 2-alkyl-6-hydroxy-4-H-benzopyran-4-one weak inhibition of isozymes 15-hLO-1 and 15-hLO-2 68691 1.13.11.33 2-hydroxybenzoic acid 46.0% inhibition at 0.015 mM, active site binding structure 5097 1.13.11.33 2-phenyl-3-[3-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-5-yl]-1H-indole molecular docking, compound is stabilized in the catalytic pocket of enzyme by pi-cation interaction with the catalytic Fe+ and formation of one hydrogen bond with Ile 676 amino acid 261177 1.13.11.33 2-[2-(1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione - 134828 1.13.11.33 2-[2-(2-bromo-1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione - 134830 1.13.11.33 2-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-1H-isoindole-1,3(2H)-dione - 134846 1.13.11.33 2-[3-(1H-indol-3-yl)propyl]-1H-isoindole-1,3(2H)-dione - 134829 1.13.11.33 2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethan-1-amine - 220072 1.13.11.33 2-[[(4-bromophenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2 261214 1.13.11.33 2-[[(4-ethylphenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2 261215 1.13.11.33 3'-chloro-7,8-dihydroxyisoflavone weak inhibition of isozyme 15-hLO-2 25425 1.13.11.33 3'-naphthalen-2-yl-1'-phenyl-5-p-tolyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 262280 1.13.11.33 3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 262279 1.13.11.33 3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazole compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 262277 1.13.11.33 3,4,5-Trihydroxybenzoic acid 60.5% inhibition at 0.015 mM, active site binding structure 4477 1.13.11.33 3,4,6,8-tetrabromooxanthren-1-ol IC50: 0.0009 mM 23037 1.13.11.33 3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol IC50: 0.009 mM 13657 1.13.11.33 3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol IC50: 0.005 mM 13657 1.13.11.33 3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol IC50: 0.011 mM 23035 1.13.11.33 3,4-dihydroxybenzoic acid 51.6% inhibition at 0.015 mM, active site binding structure; 73.3% inhibition at 0.015 mM, active site binding structure 1781 1.13.11.33 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one IC50: 0.05 mM 7628 1.13.11.33 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one IC50: 0.015 mM 7628 1.13.11.33 3,5-Dihydroxybenzoic acid 58.1% inhibition at 0.015 mM, active site binding structure 7110 1.13.11.33 3,6,8-tribromooxanthren-1-ol IC50: 0.0008 mM 23038 1.13.11.33 3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylic acid - 134826 1.13.11.33 3-(4-bromophenyl)-6-(4-chlorophenyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine - 220170 1.13.11.33 3-(4-bromophenyl)-6-(4-chlorophenyl)-N-cyclohexylimidazo[2,1-b][1,3]thiazol-5-amine - 220166 1.13.11.33 3-(4-bromophenyl)-N-cyclohexyl-6-(2-nitrophenyl)imidazo[2,1-b][1,3]thiazol-5-amine - 220161 1.13.11.33 3-(4-methoxyphenyl)-5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-1,2-oxazole compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 261294 1.13.11.33 3-(4-methoxyphenyl)-6-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine protective activity of compound 5i against H2O2-induced cell death in differentiated PC12 cells 220169 1.13.11.33 3-hydroxy-H-benzopyran-4-one derivatives weak inhibition of isozymes 15-hLO-1 and 15-hLO-2 143380 1.13.11.33 3-Hydroxybenzoic acid 47.6% inhibition at 0.015 mM, active site binding structure 3970 1.13.11.33 3-[1-[(4-pentylphenyl)sulfonyl]pyrrolidin-3-yl]-1H-indole - 134817 1.13.11.33 3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide IC50: 0.059 mM 13658 1.13.11.33 3-[[(4-methylphenyl)methyl]sulfanyl]-1-phenyl-1H-1,2,4-triazole mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2 261359 1.13.11.33 4',6,7-trihydroxyisoflavan - 18632 1.13.11.33 4',6,7-trihydroxyisoflavanone weak inhibition of isozyme 15-hLO-2 18636 1.13.11.33 4',6,7-trihydroxyisoflavone weak inhibition of isozyme 15-hLO-2 25428 1.13.11.33 4'-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide IC50: 0.00053 mM in the presence of arachidonate, IC50: 0.0002 mM in the presence of linoleic acid 61395 1.13.11.33 4'-chloro-7,8-dihydroxyisoflavone weak inhibition of isozyme 15-hLO-2 25424 1.13.11.33 4'-ethyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide IC50: 0.00026 mM in the presence of arachidonate, IC50: 0.00047 mM in the presence of linoleic acid 61393 1.13.11.33 4'-tert-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide IC50: 0.00027 mM in the presence of arachidonate, IC50: 0.00023 mM in the presence of linoleic acid 61397 1.13.11.33 4,4'-(2,3-dimethylbutane-1,4-diyl)di(benzene-1,2-diol) - 220065 1.13.11.33 4,4'-propane-2,2-diylbis(2,6-dibromophenol) IC50: 0.004 mM 23040 1.13.11.33 4,5-bis(4-chlorophenyl)-1H-imidazole-2-thiol - 192896 1.13.11.33 4,5-bis(4-fluorophenyl)-1H-imidazole-2-thiol - 192897 1.13.11.33 4,5-bis(4-methoxyphenyl)-1H-imidazole-2-thiol - 192898 1.13.11.33 4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220119 1.13.11.33 4,5-diphenyl-1H-imidazole-2-thiol - 192899 1.13.11.33 4,7,10,13-eicosatetraenoic acid - 51380 1.13.11.33 4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate - 83869 1.13.11.33 4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate - 83870 1.13.11.33 4-(2-benzoylhydrazinyl)benzene-1-sulfonamide 10% inhibition 220151 1.13.11.33 4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide - 37539 1.13.11.33 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine - 220073 1.13.11.33 4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide - 37540 1.13.11.33 4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide - 37541 1.13.11.33 4-(4-chlorophenyl)-5-phenyl-1H-imidazole-2-thiol - 192919 1.13.11.33 4-(4-methoxyphenyl)-5-phenyl-1H-imidazole-2-thiol - 192920 1.13.11.33 4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83865 1.13.11.33 4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83860 1.13.11.33 4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83857 1.13.11.33 4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83864 1.13.11.33 4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83858 1.13.11.33 4-(5-(3-hydroxynaphthalen-2-yl)-1,3,4-oxadiazol-2-ylthio)-but-2-ynyl-4-fluorobenzoate low solubility 163547 1.13.11.33 4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83861 1.13.11.33 4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83859 1.13.11.33 4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83862 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate - 83868 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol - 83871 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate - 83852 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate - 83851 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate - 83850 1.13.11.33 4-(5-(naphthalen-1-yl)-1,3,4-thiadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate low solubility 163548 1.13.11.33 4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83866 1.13.11.33 4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83863 1.13.11.33 4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate - 83856 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(3-hydroxypropyl)benzamide - 134856 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(4-methoxyphenyl)benzamide - 134852 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-butylbenzamide - 134853 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-cyclohexylbenzamide - 134854 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-phenylbenzamide - 134851 1.13.11.33 4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-[3-(dimethylamino)propyl]benzamide - 134857 1.13.11.33 4-([2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]sulfamoyl)benzoic acid - 134834 1.13.11.33 4-allyl-2-methoxyphenyl 1-adamantanecarboxylate - 37666 1.13.11.33 4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate - 37665 1.13.11.33 4-allyl-2-methoxyphenyl 2-chlorobenzoate - 37657 1.13.11.33 4-allyl-2-methoxyphenyl 2-fluorobenzoate - 37654 1.13.11.33 4-allyl-2-methoxyphenyl 2-methylbenzoate - 37660 1.13.11.33 4-allyl-2-methoxyphenyl 2-pyridinecarboxylate - 37651 1.13.11.33 4-allyl-2-methoxyphenyl 3-chlorobenzoate - 37658 1.13.11.33 4-allyl-2-methoxyphenyl 3-fluorobenzoate - 37655 1.13.11.33 4-allyl-2-methoxyphenyl 3-methoxybenzoate - 37663 1.13.11.33 4-allyl-2-methoxyphenyl 3-methylbenzoate - 37661 1.13.11.33 4-allyl-2-methoxyphenyl 4-chlorobenzoate - 37659 1.13.11.33 4-allyl-2-methoxyphenyl 4-fluorobenzoate - 37656 1.13.11.33 4-allyl-2-methoxyphenyl 4-methoxybenzoate - 37664 1.13.11.33 4-allyl-2-methoxyphenyl 4-methylbenzoate - 37662 1.13.11.33 4-allyl-2-methoxyphenyl benzoate - 37650 1.13.11.33 4-allyl-2-methoxyphenyl isonicotinate - 37653 1.13.11.33 4-allyl-2-methoxyphenyl nicotinate - 37652 1.13.11.33 4-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220133 1.13.11.33 4-bromo-5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220122 1.13.11.33 4-bromo-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220121 1.13.11.33 4-bromo-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide - 134814 1.13.11.33 4-Bromophenol IC50: 0.048 mM 3974 1.13.11.33 4-Bromophenol IC50: 0.055 mM 3974 1.13.11.33 4-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220114 1.13.11.33 4-butyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide IC50: 0.00307 mM in the presence of arachidonate, IC50: 0.004 mM in the presence of linoleic acid 61387 1.13.11.33 4-butyl-N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]benzenesulfonamide - 134832 1.13.11.33 4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide - 37544 1.13.11.33 4-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220117 1.13.11.33 4-chloro-N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide - 220130 1.13.11.33 4-chloro-N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide - 220128 1.13.11.33 4-chlorophenyl 3-[(2-chlorophenyl)carbamoyl]-1H-pyrazole-1-carboxylate - 220078 1.13.11.33 4-ethyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid 61385 1.13.11.33 4-hydroxy-3-methoxybenzoic acid 45.4% inhibition at 0.015 mM, active site binding structure 9611 1.13.11.33 4-hydroxybenzoic acid 47.0% inhibition at 0.015 mM, active site binding structure 1858 1.13.11.33 4-methyl-2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 67990 1.13.11.33 4-methyl-2-(4-hydroxypiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 68696 1.13.11.33 4-methyl-2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 25286 1.13.11.33 4-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine - 262273 1.13.11.33 4-methyl-2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 25287 1.13.11.33 4-methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 68697 1.13.11.33 4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine - 25429 1.13.11.33 4-methyl-2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 25288 1.13.11.33 4-methyl-2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine - 25289 1.13.11.33 4-nitrocatechol IC50: 0.0046 mM 1492 1.13.11.33 4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide - 37547 1.13.11.33 4-pentyl-N-(2-[2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl]ethyl)benzenesulfonamide - 134839 1.13.11.33 4-pentyl-N-[2-(2-phenyl-1H-indol-3-yl)ethyl]benzenesulfonamide - 134836 1.13.11.33 4-pentyl-N-[2-(2-quinolin-3-yl-1H-indol-3-yl)ethyl]benzenesulfonamide - 134845 1.13.11.33 4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 67991 1.13.11.33 4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 67992 1.13.11.33 4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 37548 1.13.11.33 4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 67993 1.13.11.33 4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 37549 1.13.11.33 4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide - 37550 1.13.11.33 4-pentyl-N-[2-[5-(1H-pyrrol-2-yl)-1H-indol-3-yl]ethyl]benzenesulfonamide - 134827 1.13.11.33 4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide - 37551 1.13.11.33 4-[(E)-benzoyldiazenyl]benzene-1-sulfonamide - 220158 1.13.11.33 4-[(E)-benzoyldiazenyl]benzonitrile 80% inhibition, competitive 220159 1.13.11.33 4-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)-1H-imidazole-2-thiol - 192994 1.13.11.33 4-[4-(methylsulfanyl)phenyl]-5-phenyl-1H-imidazole-2-thiol - 192995 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate - 83039 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate - 83040 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate - 83036 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate - 83045 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate - 83043 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate - 83037 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate - 83049 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate - 83029 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate - 83047 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate - 83046 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate - 83055 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate - 83041 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate - 83030 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate - 83044 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate - 83053 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate - 83051 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate - 83050 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate - 83054 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate - 83056 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate - 83048 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate - 83057 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate - 83052 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate - 83042 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate - 83034 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate - 83035 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate - 83033 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate - 83032 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate - 83038 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate - 83031 1.13.11.33 4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate - 83059 1.13.11.33 4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate - 83058 1.13.11.33 4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate - 83854 1.13.11.33 4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate - 83853 1.13.11.33 4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate - 83855 1.13.11.33 5,8,11,14,17-eicosapentaenoic acid - 5496 1.13.11.33 5,8,11,14-eicosatetraenoic acid - 16909 1.13.11.33 5,8,11,14-eicosatetraenoic acid IC50: 0.00012 mM 16909 1.13.11.33 5,8,11,14-Eicosatetraynoic acid - 4214 1.13.11.33 5,8,11,14-Eicosatetraynoic acid 0.0009 mM, 50% inhibition 4214 1.13.11.33 5,8,11,14-Eicosatetraynoic acid inhibits reaction of linoleic acid 4214 1.13.11.33 5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-1'-phenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 262281 1.13.11.33 5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-2,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']-bipyrazole compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 262278 1.13.11.33 5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-3-p-tolyl-4,5-dihydro-1,2-oxazole compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency 261547 1.13.11.33 5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol - 193021 1.13.11.33 5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-(methylsulfanyl)-1H-imidazole - 193022 1.13.11.33 5-(4-chlorophenyl)-4-[4-(dimethylamino)phenyl]-1H-imidazole-2-thiol - 193023 1.13.11.33 5-(4-chlorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol - 193024 1.13.11.33 5-(4-fluorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol - 193026 1.13.11.33 5-(4-fluorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol - 193027 1.13.11.33 5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine IC50: 0.032 mM 23257 1.13.11.33 5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine IC50: 0.059 mM 23257 1.13.11.33 5-(methylamino)-2-(naphthalen-1-yl)-4,5-dihydro-1,3-oxazole-4-carbonitrile - 261555 1.13.11.33 5-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220134 1.13.11.33 5-butyl-N3-(2-chloro-4-fluorophenyl)-N1-hexyl-1H-pyrazole-1,3-dicarboxamide - 220089 1.13.11.33 5-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole - 220142 1.13.11.33 5-chloro-N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide - 261570 1.13.11.33 5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220118 1.13.11.33 5-ethoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine IC50: 0.028 mM 56680 1.13.11.33 5-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole - 220144 1.13.11.33 5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine IC50: 0.029 mM 23255 1.13.11.33 5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine IC50: 0.059 mM 23255 1.13.11.33 5-tert-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220115 1.13.11.33 6,11-dihydro[1]benzothiopyrano[4,3-b]indole PD146176 155082 1.13.11.33 6,6a,11,11a-tetrahydro[1]benzothiopyrano[4,3-b]indole - 261608 1.13.11.33 6,7-dihydroxy-2-t-butylbenzopyran-4-one weak inhibition of isozyme 15-hLO-2 68699 1.13.11.33 6,7-dihydroxy-3',4'-methylenedioxyisoflavan - 18633 1.13.11.33 6,7-dihydroxy-3'-methylisoflavan - 18634 1.13.11.33 6,7-dihydroxy-3'-methylisoflavanone weak inhibition of isozyme 15-hLO-2 18637 1.13.11.33 6,7-dihydroxy-4'-methoxyisoflavan - 18631 1.13.11.33 6,7-dihydroxy-4'-methoxyisoflavanone weak inhibition of isozyme 15-hLO-2 18635 1.13.11.33 6,7-dihydroxyisoflavones weak inhibition of isozymes 15-hLO-1 and 15-hLO-2 143379 1.13.11.33 6,7-dimethoxy-2,3-dihydrochromone IC50: 0.137 mM 62158 1.13.11.33 6,7-diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate IC50: 0.015 mM 56813 1.13.11.33 6,7-diphenylpyrrolo[1,2-b]pyridazin-5-yl trifluoromethanesulfonate IC50: 0.043 mM 56681 1.13.11.33 6,7-diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate IC50: 0.022 mM 56812 1.13.11.33 6-(2-bromophenyl)-N-cyclohexyl-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine - 220165 1.13.11.33 6-(2-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine - 220167 1.13.11.33 6-(4-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine - 220168 1.13.11.33 6-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole - 220141 1.13.11.33 6-chloro-2-(4,5-dichloro-1H-pyrazol-3-yl)-1,3-benzoxazole - 220146 1.13.11.33 6-chloro-2-(5-chloro-1H-pyrazol-3-yl)-1,3-benzoxazole - 220145 1.13.11.33 6-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole - 220143 1.13.11.33 6-hydroxy-2-pentyl-4H-benzopyran-4-one weak inhibition of isozyme 15-hLO-2 68698 1.13.11.33 6-oxo-6alpha,12alpha-dehydrodeguelin - 135222 1.13.11.33 6-[4-([1,1'-biphenyl]-2-yl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide - 220068 1.13.11.33 6-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-phenylhexan-1-one low solubility 162855 1.13.11.33 6alpha,12alpha-12alpha-hydroxyelliptone IC50: 0.062 mM 62155 1.13.11.33 6alpha,12alpha-dehydrodeguelin IC50: 0.071 mM 62156 1.13.11.33 7,10,13-eicosatrienoic acid - 51447 1.13.11.33 7,8-dihydroxy-3',4'-dimethoxyisoflavan - 18629 1.13.11.33 7,8-dihydroxy-3'-methylisoflavone weak inhibition of isozyme 15-hLO-2 25426 1.13.11.33 7,8-dihydroxy-3'-trifluoromethylisoflavone weak inhibition of isozyme 15-hLO-2 25427 1.13.11.33 7,8-dihydroxy-4'-methoxyisoflavan - 18630 1.13.11.33 7,8-dihydroxy-4'-methylisoflavan - 18628 1.13.11.33 7,8-dihydroxy-4'-methylisoflavone weak inhibition of isozyme 15-hLO-2 25422 1.13.11.33 7,8-dihydroxyisoflavone weak inhibition of isozyme 15-hLO-2 25423 1.13.11.33 7-(1,1-dimethylethyl)-2,3-diphenyl-1-indolizinol tosylate IC50: 0.022 mM 56789 1.13.11.33 7-cyano-2,3-diphenylindolizin-1-yl 2-methoxybenzoate IC50: 0.03 mM 56824 1.13.11.33 7-cyano-2,3-diphenylindolizin-1-yl 3-methoxybenzoate IC50: 0.028 mM 56823 1.13.11.33 7-cyano-2,3-diphenylindolizin-1-yl 4-methoxybenzoate IC50: 0.028 mM 56822 1.13.11.33 7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate IC50: 0.046 mM 22040 1.13.11.33 7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate IC50: 0.059 mM 22040 1.13.11.33 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine - 220070 1.13.11.33 7-hydroxy-H-benzopyran-4-one derivatives weak inhibition of isozymes 15-hLO-1 and 15-hLO-2 68693 1.13.11.33 8,11,14-eicosatrienoic acid - 4495 1.13.11.33 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one - 220069 1.13.11.33 AA-861 - 107516 1.13.11.33 AAAKKAAK 64.2% inhibition at 0.25 mM 143365 1.13.11.33 adamantyl caffeate IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.074 mM 261799 1.13.11.33 AIBRINKK - 143369 1.13.11.33 alpha-mangostin NSC30552, a natural product, caspase-3 pathway inhibitor, performs selective inhibition of 12-LO 10096 1.13.11.33 anthraquinone - 16780 1.13.11.33 apigenin IC50: 0.5 mM 515 1.13.11.33 apigenin IC50: 0.18 mM 515 1.13.11.33 apigenin IC50: 0.0034 mM without Triton X-100, IC50: 0.0003 mM in the presence of 0.01% Triton X-100 515 1.13.11.33 arachidonic acid autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations 290 1.13.11.33 ATP - 4 1.13.11.33 baicalein IC50: 0.035 mM 1102 1.13.11.33 baicalein IC50: 0.001 mM 1102 1.13.11.33 baicalein potent inhibitor, IC50: 0.0016 mM without Triton X-100, IC50: 0.038 mM in the presence of 0.01% Triton X-100 1102 1.13.11.33 baicalein - 1102 1.13.11.33 barbigerone IC50: 0.063 mM 62157 1.13.11.33 benzoic acid 48.4% inhibition at 0.015 mM, active site binding structure 498 1.13.11.33 bestatin IC50: 0.027 mM 225 1.13.11.33 bestatin 7 IC50: 0.027 mM 23041 1.13.11.33 beta-casein 11.7% inhibition at 0.025 mM 3870 1.13.11.33 BODIPY-D3825 competes with the substrate fatty acid for binding at the active site 26992 1.13.11.33 bornyl vanillate IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.401 mM 261818 1.13.11.33 BW755C - 5718 1.13.11.33 caffeic acid 36.2% inhibition at 0.015 mM 426 1.13.11.33 caffeic acid specific inhibition of 15-LO 426 1.13.11.33 caffeic acid specific inhibitor of 15-LOX-1 426 1.13.11.33 CDC CAS-No. 132465-11-3 220862 1.13.11.33 chrysin IC50: 1 mM 1727 1.13.11.33 cinnamyl 3,4-dihydroxy-cyanocinnamate CDC 68694 1.13.11.33 cinnamyl-3,4-dihydroxy-a-cyanocinnamate - 135223 1.13.11.33 cinnamyl-3,4-dihydroxy-cyanocinnamate - 220058 1.13.11.33 conjugated linoleic acids conjugated linoleic acids may function as inhibitors of 15-LO-1 activity in macrophages/in vivo, overview 143381 1.13.11.33 daidzein IC50: 0.25 mM 848 1.13.11.33 daidzein IC50: 0.43 mM 848 1.13.11.33 dansyl tryptamine IC50: 0.00373 mM 62166 1.13.11.33 decyl gallate - 22103 1.13.11.33 dysidenin - 25421 1.13.11.33 ebselen i.e. 2-phenyl-1,2-benzisoselenazol-3(2H)-one, irreversible inhibition, IC50: 0.00006 mM 2514 1.13.11.33 ebselen - 2514 1.13.11.33 eicosatetraynoic acid - 6735 1.13.11.33 epicatechin IC50: 0.06 mM 1161 1.13.11.33 esculetin - 1533 1.13.11.33 ethyl 6-([3-[(2-chloro-4-fluorophenyl)carbamoyl]-1H-pyrazole-1-carbonyl]amino)hexanoate - 220081 1.13.11.33 ethyl 6-chloro-3-[(3S)-3-hydroxy-7-methyloctanoyl]-2,3-dihydro-1H-indole-2-carboxylate - 261864 1.13.11.33 ethyl gallate - 11000 1.13.11.33 fenchyl caffeate IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.089 mM 261875 1.13.11.33 fisetin IC50: 0.0035 mM 1257 1.13.11.33 fisetin IC50: 0.0018 mM 1257 1.13.11.33 flavone IC50: 0.7 mM 1617 1.13.11.33 flavone IC50: 0.32 mM 1617 1.13.11.33 galangin IC50: 0.2 mM 2110 1.13.11.33 galangin IC50: 0.045 mM 2110 1.13.11.33 gallic acid - 764 1.13.11.33 GATA-6 inhibits non-steroidal anti-inflammatory drugs-induced transcription of 15-LOX-1 in colorectal cancer cells 155080 1.13.11.33 genistein IC50: 1 mM 377 1.13.11.33 genistein IC50: 0.018 mM 377 1.13.11.33 genistein IC50: above 0.167 mM 377 1.13.11.33 genistin IC50: above 0.167 mM 4889 1.13.11.33 glucocorticoid inhibits induction in monocytes 10010 1.13.11.33 glucosyringic acid IC50: above 0.167 mM 62147 1.13.11.33 hesperetin IC50: 0.09 mM 2081 1.13.11.33 interferon-gamma inhibits induction in monocytes 8321 1.13.11.33 iodoacetamide 1.0 mM, 30% inhibition 67 1.13.11.33 IRKEIKKN 33.9% inhibition at 0.25 mM 143368 1.13.11.33 isotachioside IC50: above 0.167 mM 62149 1.13.11.33 jaspaquinol IC50: 0.0003 mM 62164 1.13.11.33 L-carnosine 3.6% inhibition at 0.25 mM 52636 1.13.11.33 linoleic acid - 428 1.13.11.33 linoleic acid autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations 428 1.13.11.33 linoleic acid fully deuterated, the mode of inhibition, in the presence of 13-(S)-hydroxyoctadecadienoic acid, changes from mixed-type inhibition to competitive inhibition 428 1.13.11.33 luteolin IC50: 0.003 mM 436 1.13.11.33 luteolin IC50: 0.0006 mM 436 1.13.11.33 methyl 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate - 220074 1.13.11.33 methyl 3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylate - 134825 1.13.11.33 methyl gallate - 1402 1.13.11.33 michellamine B NSC661755, potent but non-selective inhibitor, a natural anti-viral agent 18625 1.13.11.33 additional information the enzyme undergoes suicidal inactivation, during fatty acid oxygenation 2 1.13.11.33 additional information IC50 above 0.1 mM: compound 1a, compound 1b, compound 1d, compound 1e, compound 1g 2 1.13.11.33 additional information docking experiments and qualitative structure-activity relationship, QSAR, data, overview 2 1.13.11.33 additional information development of an assay method for high throughput screening of libraries for platelet-type 12-hLO selective inhibitors, four organo-mercurial compounds with NCI library IDs NSC20410, NSC268879, NSC321237, and NSC321239, are also found to be selectively inhibitory, but not pursued further due to their potentially toxic side effects, overview 2 1.13.11.33 additional information comparison of structural requirements for flavonoid inhibitory potency and selectivity against platelet 12-hLO, EC 1.13.11.31, and reticulocyte 15-hLO-1 and prostate epithelial 15-hLO-2, overview, catechols are essential for high potency, isoflavones and isoflavanones tend to select against 12-hLO, isoflavans tend to select against isozyme 15-hLO-1, but few flavonoids target isozyme 15-hLO-2, molecular modeling analysis, overview 2 1.13.11.33 additional information no inhibition by 2,6-dihydroxybenzoic acid 2 1.13.11.33 additional information quantitative structure activity relationship analysis using crystal structure, PDB ID 1IK3, EC 1.13.11.12, of the enzyme in complex with 13(S)-hydroperoxy-9(Z)-2,11(E)-octadecadienoic acid, docking studies, inhibitor binding structures, overview 2 1.13.11.33 additional information docking studies, inhibitor binding structures, overview 2 1.13.11.33 additional information synthesis and evaluation of 2,4,5-tri-substituted imidazoles, which show highly potent inhibition of 15-lipoxygenase with excellent selectivity over the lipoxygenases 5-LO, EC 1.13.11.34, and platelet 12-LO, EC 1.13.11.31 2 1.13.11.33 additional information sulproston, misoprostol, and ONO-AE-248 inhibit acetylsalicylic acid-induced 15(S)-HETE production 2 1.13.11.33 additional information docking experiments and structure activity relationship, comparative studies, comparison with the crystal structure with PDB entry: 1IK3, EC 1.13.11.12, overview 2 1.13.11.33 additional information enzyme inhibition causes a decrease in amyloid-beta protein 2 1.13.11.33 additional information inhibitory and LOX binding abilities of diverse RINKKIEK peptide derivatives, overview 2 1.13.11.33 additional information 15-LOX2 in NHP cells is negatively regulated by Sp3 2 1.13.11.33 additional information intraarticular glucocorticoid treatment does not influence the 15-LO-1 enzyme in rheumatoid arthritis tissue 2 1.13.11.33 additional information physico-chemical state of the substrate and the complex equilibrium between fatty acid monomers, acid soaps and micelles may impact the reaction specificity of LOX-isoforms 2 1.13.11.33 additional information pH alterations in the near physiological range impact the iron content of LOX and thus the catalytic activity 2 1.13.11.33 additional information 15-LOX-1 can be inactivated by epigenetic silencing, hypermethylation of the CpG islands of the 15-LOX-1 promoter results in its reduced transcription in cancers, e.g. lymphomas, lung, prostate and cervix cancers. Brominated phenol esters are potent 15-LOX-1 inhibitors 2 1.13.11.33 additional information inhibitor library screening, none selectively targets LoxA over the human LOX isozymes, overview 2 1.13.11.33 additional information N-substituted pyrazole-3-carboxamides as inhibitors of human 15-lipoxygenase, overview. No inhibition by 7h and 10a 2 1.13.11.33 additional information 3-substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1, overview. The 1N-substituent is not essential for activity or selectivity. Additional halogen substituents on the pyrazole ring increase activity. Further development leads to triazole-4-carboxanilides and 2-(3-pyrazolyl) benzoxazoles, which are potent and selective 15-LOX-1 inhibitors 2 1.13.11.33 additional information synthesis and evaluation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase, overview 2 1.13.11.33 additional information imidazo[2,1-b]thiazole derivatives as inhibitors of 15-lipoxygenase, synthesis and evaluation of series of 3,6-diphenylimidazo[2,1-b]thiazol-5-amine derivatives, docking study, overview 2 1.13.11.33 additional information certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms 2 1.13.11.33 additional information stylosin and some similar synthetic monoterpenoids show inhibitory effects on 15-LOX. A strong positive correlation is observed between 15-LOX inhibition potential and cytotoxicity of the compounds with apoptosis being the predominant mechanism of induced cell death 2 1.13.11.33 morin IC50: 0.018 mM 1145 1.13.11.33 morin IC50: 0.006 mM 1145 1.13.11.33 myricetin IC50: 0.006 mM 484 1.13.11.33 myricetin IC50: 0.018 mM 484 1.13.11.33 N'-(4-bromophenyl)benzohydrazide 28% inhibition 220150 1.13.11.33 N'-(4-cyanophenyl)benzohydrazide 9% inhibition 220152 1.13.11.33 N'-(4-methoxyphenyl)benzohydrazide 73% inhibition 220147 1.13.11.33 N'-(4-methylphenyl)benzohydrazide 93% inhibition, competitive 220148 1.13.11.33 N'-(4-nitrophenyl)benzohydrazide 17% inhibition 220153 1.13.11.33 N'-phenylbenzohydrazide 33% inhibition 220149 1.13.11.33 N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide - 37583 1.13.11.33 N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide - 37584 1.13.11.33 N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide - 37585 1.13.11.33 N,2-dihydroxybenzamide IC50: 0.057 mM 51917 1.13.11.33 N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide - 220137 1.13.11.33 N-(2,5-dichlorophenyl)-1H-pyrazole-3-carboxamide - 220138 1.13.11.33 N-(2-chloro-4-fluorophenyl)-1-(dimethylsulfamoyl)-1H-pyrazole-3-carboxamide - 220085 1.13.11.33 N-(2-chloro-4-fluorophenyl)-1-(phenylacetyl)-1H-pyrazole-3-carboxamide - 220076 1.13.11.33 N-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide - 220087 1.13.11.33 N-(2-chloro-4-fluorophenyl)-1-[3-(trifluoromethyl)benzene-1-sulfonyl]-1H-pyrazole-3-carboxamide - 220084 1.13.11.33 N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220097 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4,5-bis(trifluoromethyl)-1H-pyrazole-3-carboxamide - 220127 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-(trifluoromethyl)-1H-pyrazole-3-carboxamide - 220125 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-fluoro-1H-pyrazole-3-carboxamide - 220120 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-iodo-1H-pyrazole-3-carboxamide - 220123 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide - 220112 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-methyl-5-(trimethylsilyl)-1H-pyrazole-3-carboxamide - 220111 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-nitro-1H-pyrazole-3-carboxamide - 220131 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-phenyl-1H-pyrazole-3-carboxamide - 220116 1.13.11.33 N-(2-chloro-4-fluorophenyl)-4-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide - 220135 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide - 220129 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide - 220126 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-iodo-1H-pyrazole-3-carboxamide - 220124 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxamide - 220113 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-nitro-1H-pyrazole-3-carboxamide - 220132 1.13.11.33 N-(2-chloro-4-fluorophenyl)-5-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide - 220136 1.13.11.33 N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide - 220095 1.13.11.33 N-(2-chlorophenyl)-N-methyl-1H-pyrazole-3-carboxamide - 220110 1.13.11.33 N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide - 220096 1.13.11.33 N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide - 83867 1.13.11.33 N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide - 220094 1.13.11.33 N-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazole-3-carboxamide - 220105 1.13.11.33 N-(5-chloropyridin-2-yl)-1H-pyrazole-3-carboxamide - 220104 1.13.11.33 N-(5-fluoropyridin-2-yl)-1H-pyrazole-3-carboxamide - 220103 1.13.11.33 N-(7-fluoroquinolin-3-yl)-1H-pyrazole-3-carboxamide - 220139 1.13.11.33 N-(isoquinolin-3-yl)-1H-pyrazole-3-carboxamide - 220109 1.13.11.33 N-(pyridin-2-yl)-1H-pyrazole-3-carboxamide - 220100 1.13.11.33 N-(pyridin-3-yl)-1H-pyrazole-3-carboxamide - 220101 1.13.11.33 N-(pyridin-4-yl)-1H-pyrazole-3-carboxamide - 220102 1.13.11.33 N-(quinolin-2-yl)-1H-pyrazole-3-carboxamide - 220106 1.13.11.33 N-(quinolin-3-yl)-1H-pyrazole-3-carboxamide - 220107 1.13.11.33 N-(quinolin-6-yl)-1H-pyrazole-3-carboxamide - 220108 1.13.11.33 N-(tert-butyl)-3-phenyl-6-(p-tolyl)imidazo[2,1-b]thiazol-5-amine - 220173 1.13.11.33 N-(tert-butyl)-6-(4-chlorophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine - 220172 1.13.11.33 N-(tert-butyl)-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine - 220174 1.13.11.33 N-(tert-butyl)-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine - 220171 1.13.11.33 N-benzyl-1H-pyrazole-3-carboxamide - 220093 1.13.11.33 n-butyl gallate - 113930 1.13.11.33 N-cyclohexyl-6-(2-fluorophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine - 220163 1.13.11.33 N-cyclohexyl-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine - 220164 1.13.11.33 N-cyclohexyl-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine - 220162 1.13.11.33 N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide - 37580 1.13.11.33 N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide - 37579 1.13.11.33 N-phenyl-1H-pyrazole-3-carboxamide - 220092 1.13.11.33 n-propyl gallate - 3686 1.13.11.33 n-tetradecyl gallate - 113976 1.13.11.33 N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide - 37562 1.13.11.33 N-[(5-bromo-8-hydroxy-5,6,7,8-tetrahydroquinolin-7-yl)(thiophen-2-yl)methyl]acetamide - 220063 1.13.11.33 N-[2-(1H-indol-3-yl)-1-methylethyl]-4-pentylbenzenesulfonamide - 134818 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-2'-methylbiphenyl-4-sulfonamide IC50: 0.00092 mM in the presence of arachidonate, IC50: 0.00046 mM in the presence of linoleic acid 61390 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-3'-methylbiphenyl-4-sulfonamide IC50: 0.00045 mM in the presence of arachidonate, IC50: 0.00032 mM in the presence of linoleic acid 61391 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4'-(1-methylethyl)biphenyl-4-sulfonamide IC50: 0.00028 mM in the presence of arachidonate, IC50: 0.00014 mM in the presence of linoleic acid 61394 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4'-(2-methylpropyl)biphenyl-4-sulfonamide IC50: 0.00091 mM in the presence of arachidonate, IC50: 0.00017 mM in the presence of linoleic acid 61396 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4'-methoxybiphenyl-4-sulfonamide IC50: 0.0015 mM in the presence of arachidonate, IC50: 0.00109 mM in the presence of linoleic acid 61398 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4'-methylbiphenyl-4-sulfonamide IC50: 0.00047 mM in the presence of linoleic acid 61392 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid 61384 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide IC50: 0.00042 mM in the presence of arachidonate, IC50: 0.00102 mM in the presence of linoleic acid 61388 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-4-propylbenzenesulfonamide IC50: 0.00313 mM in the presence of arachidonate, IC50: 0.0032 mM in the presence of linoleic acid 61386 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]-N-methyl-4-pentylbenzenesulfonamide - 134815 1.13.11.33 N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide IC50: 0.0034 mM in the presence of arachidonate, IC50: 0.0042 mM in the presence of linoleic acid 61389 1.13.11.33 N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide - 37565 1.13.11.33 N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide - 37566 1.13.11.33 N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide - 37563 1.13.11.33 N-[2-(2-dibenzo[b,d]furan-2-yl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide - 134844 1.13.11.33 N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide - 68100 1.13.11.33 N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide - 37564 1.13.11.33 N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide - 134823 1.13.11.33 N-[2-(5-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide - 134822 1.13.11.33 N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide - 134824 1.13.11.33 N-[2-(7-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide - 134821 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1-methyl-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134847 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-(hydrazinocarbonyl)benzenesulfonamide - 134855 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-bromobenzenesulfonamide - 134849 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide - 134848 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134841 1.13.11.33 N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pyridin-4-ylbenzenesulfonamide - 134850 1.13.11.33 N-[2-[2-(2,5-dimethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134840 1.13.11.33 N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 68103 1.13.11.33 N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 37568 1.13.11.33 N-[2-[2-(4-chlorophenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134837 1.13.11.33 N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 37569 1.13.11.33 N-[2-[2-(4-ethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134838 1.13.11.33 N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide - 134831 1.13.11.33 N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide - 134833 1.13.11.33 N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]biphenyl-4-sulfonamide - 134835 1.13.11.33 N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 68104 1.13.11.33 N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 68105 1.13.11.33 N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 37570 1.13.11.33 N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 37571 1.13.11.33 N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide - 37572 1.13.11.33 N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide - 37573 1.13.11.33 N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide - 37574 1.13.11.33 N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide - 37575 1.13.11.33 N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide - 37576 1.13.11.33 N-[3-(1H-indol-3-yl)propyl]-4-pentylbenzenesulfonamide - 134819 1.13.11.33 N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide - 37577 1.13.11.33 N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]-4-pentylbenzenesulfonamide - 134842 1.13.11.33 N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]biphenyl-4-sulfonamide - 134843 1.13.11.33 N-[4-(1H-indol-3-yl)butyl]-4-pentylbenzenesulfonamide - 134820 1.13.11.33 N-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide - 220098 1.13.11.33 N-[4-fluoro-2-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide - 220099 1.13.11.33 N1-(2H-1,3-benzodioxol-5-yl)-N-3-(2-chloro-4-fluorophenyl)-1H-pyrazole-1,3-dicarboxamide - 220079 1.13.11.33 N1-butyl-N3-(2-chlorophenyl)-N3-methyl-1H-pyrazole-1,3-dicarboxamide - 220091 1.13.11.33 N3-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-N1-hexyl-5-methyl-1H-pyrazole-1,3-dicarboxamide - 220088 1.13.11.33 N3-(2-chloro-4-fluorophenyl)-N1-hexyl-4-methyl-1H-pyrazole-1,3-dicarboxamide - 220090 1.13.11.33 N3-(2-chloro-4-fluorophenyl)-N1-pentyl-1H-pyrazole-1,3-dicarboxamide - 220080 1.13.11.33 N3-(2-chlorophenyl)-N1,N1-dimethyl-1H-pyrazole-1,3-dicarboxamide - 220082 1.13.11.33 naringenin IC50: 0.25 mM 586 1.13.11.33 NDGA - 143361 1.13.11.33 neodysidenin natural product from marine sponge Dysidea herbacea from Papua New Guinea, extraction and purification, overview, steady-state inhibition kinetics, competitive mode of inhibition, selective for 12-LO 14338 1.13.11.33 nor-dihydro-guaiaretic acid - 155081 1.13.11.33 nordihydroguaiaretic acid - 926 1.13.11.33 nordihydroguaiaretic acid 0.002 mM, 50% inhibition 926 1.13.11.33 nordihydroguaiaretic acid IC50: 0.0005 mM 926 1.13.11.33 nordihydroguaiaretic acid IC50: 0.0018 mM 926 1.13.11.33 nordihydroguaiaretic acid IC50: 0.00011 mM 926 1.13.11.33 nordihydroguaiaretic acid 0.0001-0.001 mM 926 1.13.11.33 NSC172033 a synthetic compound from the NCI library 18626 1.13.11.33 NSC292213 a synthetic compound from the NCI library 11565 1.13.11.33 NSC617570 a synthetic compound from the NCI library 18627 1.13.11.33 NVPGEIVE 65.0% inhibition at 0.25 mM 143371 1.13.11.33 octyl gallate - 5742 1.13.11.33 PCMB 0.1 mM, 30% inhibition 78 1.13.11.33 PD 146 176 IC50: 0.00038 mM 51868 1.13.11.33 PD-146176 IC50: 0.00381 mM 62163 1.13.11.33 PD146176 - 18638 1.13.11.33 PD146176 selective inhibitor of 12/15-LOX, macrophages treated with PD146176 elaborate reduced levels of interleukin-12 in response to Toxoplasma gondii antigen 18638 1.13.11.33 phenyl[(E)-phenyldiazenyl]methanone 87% inhibition 220156 1.13.11.33 PKYPVEPFTE 74.6% inhibition at 0.25 mM 143370 1.13.11.33 poly-Lys KKKKKKKK 143364 1.13.11.33 propyl gallate 96% inhibition at 0.05 mM 1879 1.13.11.33 quercetin IC50: 0.0045 mM 137 1.13.11.33 quercetin IC50: 0.004 mM 137 1.13.11.33 quercetin IC50: 0.029 mM 137 1.13.11.33 quercetin - 137 1.13.11.33 RINKKIEK 68.1% inhibition at 0.25 mM, a beta-casein-derived octapeptide 143362 1.13.11.33 RINKKIPK 57.7% inhibition at 0.25 mM 143367 1.13.11.33 RINKKISK - 143363 1.13.11.33 rutin IC50: 1 mM 1095 1.13.11.33 sarcolobin IC50: 0.06 mM 62150 1.13.11.33 siRNA cholesterol-tagged siRNAs targeting mouse leukocyte 12/15-LO reduce 12/15-LO expression in the kidney and confer beneficial effects on diabetes-induced changes in glomerular structure and ECM accumulation 772 1.13.11.33 siRNA - 772 1.13.11.33 siRNA knockdown of 15-LOX-2 expression, decreases chemokine ligand CXCL10 secretion from hypoxic macrophages and reduces T cell migration and CD69 expression 772 1.13.11.33 SITRINKK 65.3% inhibition at 0.25 mM 143366 1.13.11.33 squalene IC50 is 0.0012 mM 496 1.13.11.33 stylosin IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.101 mM 262143 1.13.11.33 tachioside IC50: above 0.167 mM 62148 1.13.11.33 taxifolin IC50: 1 mM 3233 1.13.11.33 taxifolin IC50: 0.025 mM 3233 1.13.11.33 tephrosin IC50: 0.064 mM 62151 1.13.11.33 tert-butylhydroxyanisol IC50: 0.16 mM 51938 1.13.11.33 Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester IC50: 0.017 mM 23256 1.13.11.33 Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester IC50: 0.028 mM 23256 1.13.11.33 toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester IC50: 0.017mM 23287 1.13.11.33 toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester IC50: 0.025 mM 23287 1.13.11.33 vanillic acid 4-O-beta-D-glucoside IC50: 0.161 mM 62146 1.13.11.33 villosinol - 135221 1.13.11.33 [(E)-(4-bromophenyl)diazenyl](phenyl)methanone 44% inhibition 220157 1.13.11.33 [(E)-(4-methoxyphenyl)diazenyl](phenyl)methanone 19% inhibition 220154 1.13.11.33 [(E)-(4-methylphenyl)diazenyl](phenyl)methanone 44% inhibition 220155 1.13.11.33 [(E)-(4-nitrophenyl)diazenyl](phenyl)methanone 34% inhibition 220160